The cancer drug that almost wasn't

See allHide authors and affiliations

Science  22 Aug 2014:
Vol. 345, Issue 6199, pp. 865-867
DOI: 10.1126/science.345.6199.865

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A cancer drug discovered in 2001 that targets the cell cycle has recently shown promising efficacy in metastatic breast cancer. Pfizer's palbociclib, added to standard therapy, doubles the time women live with no new tumor growth. The drug, which inhibits a cell cycle protein called CDK4, has erased the legacy of failure of other cell cycle cancer therapies, and competitors have introduced their own versions, which show promise in multiple tumor types. But the drug could have emerged much sooner, say palbociclib's inventors, had Pfizer used a more sophisticated development strategy and not shelved the drug for much of the last decade. Pfizer disagrees, but it was only after outside investigators demonstrated palbociclib's potential in breast cancer that the company moved the drug forward.

  • * Ken Garber is a writer in Ann Arbor, Michigan.

View Full Text

Stay Connected to Science